Shares of PROCEPT BioRobotics (NASDAQ: PRCT) are set to open sharply lower on Wednesday, plummeting 5.20% in pre-market trading. The decline comes in the wake of the surgical robotics company's third-quarter earnings report and 2026 revenue guidance release, which have left investors concerned about future growth prospects despite strong current performance.

PROCEPT BioRobotics reported better-than-expected third-quarter results, with revenue of $83.3 million surpassing analyst estimates of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's pre-market plunge, as investors had likely anticipated more aggressive growth projections for the coming year. The market reaction has also prompted several analysts to cut their price targets for PROCEPT BioRobotics, including Jefferies, Leerink Partners, and Wells Fargo.